Efficacy and Safety of Once-Weekly Semaglutide vs. Sitagliptin as Add-on to Metformin and/or Thiazolidinediones after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 2)

Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 development for type 2 diabetes (T2D). In this 56-week, double-blind, double-dummy study, 1231 subjects with T2D on metformin (MET) and/or thiazolidinediones (TZDs) were randomized 1:1:1 to once-weekly semaglutide 0.5 mg or 1.0 mg or sitagliptin 100 mg once-daily. Primary endpoint was change in glycated hemoglobin (HbA1c).